Boston Life Sciences gets ADHD patent

By Elaine Rigoli

Tampa, Fla., Aug. 10 - Boston Life Sciences, Inc. announced that the U.S. Patent and Trademark Office has issued a patent to the president and fellows of Harvard College, the General Hospital Corp. and Organix, Inc. covering methods of diagnosing and monitoring attention deficit hyperactivity disorder (ADHD).

The patent is exclusively licensed to Boston Life Sciences under a worldwide licensing arrangement between Boston Life Sciences and Harvard, according to a news release.

The patent claims a variety of diagnostic and monitoring methods for assessing ADHD using labeled compounds that bind to the dopamine transporter and are measured using any imaging technique including single photon emission computed tomography and positron emission tomography.

Boston Life Sciences is a medical research company based in Hopkinton, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.